Last10K.com

Fate Therapeutics Inc (FATE) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2018

Fate Therapeutics Inc

HISTORY TOOLS
CIK: 1434316 Ticker: FATE

Exhibit 99.1

Fate Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress

First Patient Treated with FT500 Off-the-Shelf NK Cell Cancer Immunotherapy in Landmark Clinical Trial

Marks First-ever Human Administration of iPSC-derived Cell Therapy in the United States

$201 Million in Cash & Short-term Investments as of December 31, 2018

 

San Diego, CA – March 5, 2019 – Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2018.

 

“We achieved an unprecedented milestone in treating the first patient with FT500, which is the first-ever administration of an iPSC-derived cell therapy to a patient in the U.S. In 2018, we made great strides toward our vision of using master iPSC lines to produce universal, off-the-shelf cell-based cancer immunotherapies that are available ‘on demand’ and deliver transformational change in patient outcomes,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. “The year was also highlighted by strong clinical execution and encouraging patient data for our ongoing allogeneic cell therapy programs, ProTmune and FATE-NK100. Additionally, our industry-leading iPSC product platform delivered multiple highly differentiated, off-the-shelf NK cell and T-cell product candidates, which we expect to move into the clinic in 2019.”

 

Clinical Programs

 

•

First-ever iPSC-derived Cell Product FT500 Administered to a Patient in the U.S. In November 2018, the U.S. Food and Drug Administration (FDA) cleared the Company’s Investigational New Drug (IND) application for FT500, a universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line. The landmark clinical trial is intended to assess the safety and efficacy of multiple doses of FT500 over multiple dosing cycles for the treatment of advanced solid tumors as a monotherapy and as a combination with nivolumab, pembrolizumab or atezolizumab in patients that failed to respond to, or progressed on, checkpoint inhibitor therapy. The first subject was treated with FT500 in February 2019.

 

•

Anti-Tumor Activity of FATE-NK100 Observed Across Three Phase 1 Studies. In November 2018, the Company reported initial dose-escalation clinical data of FATE-NK100 from fifteen subjects across three Phase 1 clinical trials for the treatment of relapsed / refractory acute myelogenous leukemia, recurrent ovarian cancer and advanced solid tumors. As of an October 22, 2018 data cutoff, no FATE-NK100-related dose limiting toxicities were reported, and anti-tumor activity was

 

The following information was filed by Fate Therapeutics Inc (FATE) on Tuesday, March 5, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Fate Therapeutics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Fate Therapeutics Inc.

Continue

Assess how Fate Therapeutics Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Fate Therapeutics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Other
Filter Subcategory:
All
Expense
Shares
Cash Flow
Product
Debt
Geography
Other
Inside Fate Therapeutics Inc's 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Convertible Preferred Stock And Stockholders' Equity
Consolidated Statements Of Operations And Comprehensive Loss
Accrued Expenses, Long-Term Debt, Commitments And Contingencies
Accrued Expenses, Long-Term Debt, Commitments And Contingencies (Details 2)
Accrued Expenses, Long-Term Debt, Commitments And Contingencies (Details 3)
Accrued Expenses, Long-Term Debt, Commitments And Contingencies (Details 4)
Accrued Expenses, Long-Term Debt, Commitments And Contingencies (Details)
Accrued Expenses, Long-Term Debt, Commitments And Contingencies (Tables)
California Institute For Regenerative Medicine Award
California Institute For Regenerative Medicine Award (Details)
Collaboration And License Agreements
Collaboration And License Agreements (Details)
Convertible Preferred Stock And Stockholders' Equity
Convertible Preferred Stock And Stockholders' Equity (Details 2)
Convertible Preferred Stock And Stockholders' Equity (Details 3)
Convertible Preferred Stock And Stockholders' Equity (Details 4)
Convertible Preferred Stock And Stockholders' Equity (Details 5)
Convertible Preferred Stock And Stockholders' Equity (Details 6)
Convertible Preferred Stock And Stockholders' Equity (Details)
Convertible Preferred Stock And Stockholders' Equity (Tables)
Employee Benefits
Employee Benefits (Details)
Income Taxes
Income Taxes (Details 2)
Income Taxes (Details 3)
Income Taxes (Details 4)
Income Taxes (Details 5)
Income Taxes (Details)
Income Taxes (Tables)
Organization And Summary Of Significant Accounting Policies
Organization And Summary Of Significant Accounting Policies (Details 2)
Organization And Summary Of Significant Accounting Policies (Details 3)
Organization And Summary Of Significant Accounting Policies (Details 4)
Organization And Summary Of Significant Accounting Policies (Details 5)
Organization And Summary Of Significant Accounting Policies (Details 6)
Organization And Summary Of Significant Accounting Policies (Details)
Organization And Summary Of Significant Accounting Policies (Policies)
Organization And Summary Of Significant Accounting Policies (Tables)
Property And Equipment
Property And Equipment (Details)
Property And Equipment (Tables)
Selected Quarterly Financial Data
Selected Quarterly Financial Data (Details)
Selected Quarterly Financial Data (Tables)
Short-Term Investments
Short-Term Investments (Details 2)
Short-Term Investments (Details)
Short-Term Investments (Tables)
Ticker: FATE
CIK: 1434316
Form Type: 10-K Annual Report
Accession Number: 0001564590-19-006258
Submitted to the SEC: Tue Mar 05 2019 11:04:48 AM EST
Accepted by the SEC: Tue Mar 05 2019
Period: Monday, December 31, 2018
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/fate/0001564590-19-006258.htm